Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 36

Cited In for PubMed (Select 11419425)

1.
2.

Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Bledzka K, Smyth SS, Plow EF.

Circ Res. 2013 Apr 12;112(8):1189-200. doi: 10.1161/CIRCRESAHA.112.300570. Review.

3.

Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?

Berger PB, Williams JB, Hasselblad V, Chiswell K, Pieper KS, Califf RM.

J Interv Cardiol. 2013 Apr;26(2):123-30. doi: 10.1111/j.1540-8183.2013.12020.x. Epub 2013 Feb 5.

4.

Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review.

Kumar R, Singh N, Singh K, Kalhan A, Prasad KK.

Indian J Clin Biochem. 2004 Jan;19(1):122-8. doi: 10.1007/BF02872406.

5.

Newer agents in antiplatelet therapy: a review.

Yeung J, Holinstat M.

J Blood Med. 2012;3:33-42. doi: 10.2147/JBM.S25421. Epub 2012 Jun 25. Erratum in: J Blood Med. 2012;3:49.

7.

Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI.

Chest. 2012 Feb;141(2 Suppl):e89S-119S. doi: 10.1378/chest.11-2293. Review.

8.

Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.

Schneider DJ.

Br J Clin Pharmacol. 2011 Oct;72(4):672-82. doi: 10.1111/j.1365-2125.2010.03879.x. Review.

9.

Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis.

Wu Y, Shi Y, Wu H, Bian C, Tang Q, Xu G, Yang J.

PLoS One. 2011;6(6):e20759. doi: 10.1371/journal.pone.0020759. Epub 2011 Jun 3.

10.

Use of antiplatelet inhibitors in peripheral vascular interventions.

Stavropoulos SW, Shlansky-Goldberg RD.

Semin Intervent Radiol. 2005 Jun;22(2):80-7. doi: 10.1055/s-2005-871862.

11.

GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin.

Schiariti M, Saladini A, Papalia F, Grillo P, Nesta C, Cuturello D, Missiroli B, Puddu PE.

Open Cardiovasc Med J. 2010 Jul 20;4:151-6. doi: 10.2174/1874192401004010151.

12.

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

Pham SV, Pham PC, Pham PM, Miller JM, Pham PT, Pham PA.

Drug Des Devel Ther. 2010 Sep 7;4:203-20. doi: 10.2147/DDDT.S12056. Review.

13.

Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates.

Tucker EI, Marzec UM, Berny MA, Hurst S, Bunting S, McCarty OJ, Gruber A, Hanson SR.

Sci Transl Med. 2010 Jun 23;2(37):37ra45. doi: 10.1126/scitranslmed.3000697.

14.

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.

Vergara-Jimenez J, Tricoci P.

Vasc Health Risk Manag. 2010 Mar 3;6:39-45. Review.

15.

Abciximab: a reappraisal of its use in coronary care.

Valgimigli M, Campo G, Tebaldi M, Carletti R, Arcozzi C, Ferrari R, Percoco G.

Biologics. 2008 Mar;2(1):29-39.

16.
17.

Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review.

Hashemzadeh M, Furukawa M, Goldsberry S, Movahed MR.

Exp Clin Cardiol. 2008 Winter;13(4):192-7.

18.

Editorial on hypothesis and objectives in clinical trials: superiority, equivalence and non-inferiority.

Gonzalez CD, Bolaños R, de Sereday M.

Thromb J. 2009 Mar 21;7:3. doi: 10.1186/1477-9560-7-3. No abstract available.

19.

A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention.

Moon JY, Kim W, Kim JH, Ahn Y, Jeong MH, Kim YH, Hong MK, Park SW, Park SJ, Park S, Ko YG, Choi D, Jang Y.

Yonsei Med J. 2008 Jun 30;49(3):389-99. doi: 10.3349/ymj.2008.49.3.389.

20.

Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.

van Werkum JW, Gerritsen WB, Kelder JC, Hackeng CM, Ernst SM, Deneer VH, Suttorp MJ, Rensing BJ, Plokker HW, Ten Berg JM.

Neth Heart J. 2007;15(11):375-81.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk